Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute lymphoblastic leukemia in infancy.

Lewis B Silverman1

  • 1Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital, Boston, Massachusetts 02115, USA. lewis_silverman@dfci.harvard.edu

Pediatric Blood & Cancer
|October 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paediatric B-lymphoblastic leukaemia with low peripheral blasts: a potential diagnostic pitfall.

Journal of clinical pathology·2026
Same author

Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.

Clinical pharmacology and therapeutics·2026
Same author

Copper depletion boosts CNS leukemia therapy by inhibiting nucleotide synthesis through impairment of mitochondrial complex IV activity.

Nature cancer·2026
Same author

Altered immune and treatment response gene expression signatures among povertyexposed children with B-cell acute lymphoblastic leukemia.

Haematologica·2026
Same author

Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group.

Blood advances·2026
Same author

A lipid-immune network signature defines susceptibility to asparaginase-associated pancreatitis.

JCI insight·2026

Infant acute lymphoblastic leukemia (ALL) has unique features and poor prognosis, often linked to MLL gene rearrangements. Research focuses on intensive chemotherapy and targeted therapies like FLT3-inhibitors to improve outcomes.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Molecular Biology

Background:

  • Infant acute lymphoblastic leukemia (ALL) is rare and distinct from childhood ALL.
  • It is associated with a poor prognosis and specific adverse factors.
  • MLL gene rearrangements are found in up to 80% of infant ALL cases.

Purpose of the Study:

  • To summarize the unique characteristics of infant ALL.
  • To outline adverse prognostic factors in infant ALL.
  • To discuss current and future therapeutic strategies for infant ALL.

Main Methods:

  • Review of existing literature on infant ALL.
  • Analysis of prognostic factors, including MLL gene rearrangements.
  • Evaluation of current treatment approaches and novel therapies.

Related Experiment Videos

Main Results:

  • Infant ALL presents unique biological features and a poorer prognosis compared to older children.
  • Key adverse prognostic factors include MLL gene rearrangements, young age, high leukocyte counts, and slow treatment response.
  • The role of stem cell transplant in first remission is still debated.

Conclusions:

  • Infant ALL requires distinct therapeutic strategies due to its unique biology.
  • Ongoing research focuses on intensive cytarabine regimens and targeted therapies like FLT3-inhibitors for MLL-rearranged infant ALL.
  • Improving outcomes for infants with ALL remains a critical challenge in pediatric oncology.